Assembly Bill A6493

2019-2020 Legislative Session

Establishes the sickle cell treatment act of 2019; appropriation

download bill text pdf

Sponsored By

Archive: Last Bill Status - In Assembly Committee


  • Introduced
    • In Committee Assembly
    • In Committee Senate
    • On Floor Calendar Assembly
    • On Floor Calendar Senate
    • Passed Assembly
    • Passed Senate
  • Delivered to Governor
  • Signed By Governor

Do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.
Actions

co-Sponsors

multi-Sponsors

2019-A6493 (ACTIVE) - Details

See Senate Version of this Bill:
S2281
Current Committee:
Assembly Health
Law Section:
Appropriations
Laws Affected:
Amd §365, Soc Serv L; add Art 31 Title 4 §3126, Pub Health L
Versions Introduced in Other Legislative Sessions:
2013-2014: S6239
2015-2016: S3256
2017-2018: A5313, S4054

2019-A6493 (ACTIVE) - Summary

Furnishes preventive medicine to those with sickle cell, establishes prevention and treatment of sickle cell disease demonstration programs, and makes an appropriation thereto.

2019-A6493 (ACTIVE) - Bill Text download pdf

                            
 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   6493
 
                        2019-2020 Regular Sessions
 
                           I N  A S S E M B L Y
 
                               March 8, 2019
                                ___________
 
 Introduced  by  M.  of  A.  HYNDMAN,  JEAN-PIERRE, BLAKE, BARRON, PERRY,
   WRIGHT, JOYNER, TAYLOR, PICHARDO,  DICKENS,  BICHOTTE,  MOSLEY,  NIOU,
   DAVILA, PEOPLES-STOKES, DE LA ROSA, BARNWELL, RA, GALEF -- Multi-Spon-
   sored  by  --  M. of A. COOK, PRETLOW, SIMON, SIMOTAS -- read once and
   referred to the Committee on Health

 AN ACT to amend the social services law and the public  health  law,  in
   relation  to  establishing  the sickle cell treatment act of 2019; and
   making an appropriation therefor
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1.  This  act  shall be known and may be cited as the "Sickle
 Cell Treatment Act of 2019".
   § 2. Legislative findings. The legislature hereby finds  and  declares
 the following:
   (1)  Sickle  cell  disease  (SCD) is an inherited disease of red blood
 cells and the CDC (Centers for Disease Control) states  that  SCD  is  a
 major  public  health  concern.  Approximately 1,000 American babies are
 born with the disease each year, while globally 500,000 babies are  born
 annually with the disease.
   (2) Sickle cell disease affects approximately 100,000 Americans and is
 most  common in African-Americans as well as those of Hispanic, Mediter-
 ranean and Middle Eastern ancestry. Nationally, SCD occurs  in  approxi-
 mately  1:500  African-Americans, 1:36,000 Hispanics and 1:80,000 Cauca-
 sians. However, in NYS (New York State) SCD occurs in 1:230 live  births
 to  non-Hispanic  black  mothers, 1:2,320 births to Hispanic mothers and
 1:41,647 Caucasian mothers.
   (3) Approximately 10% of SCD patients reside in NYS. In  NYS,  1:1,146
 live  births  have  sickle  cell  disease,  with  12% of NYS sickle cell
 disease births in the Hispanic population. Higher birth  rates  for  SCD
 occur  in mothers who were born outside of the US. In NYS, approximately
 80% of sickle cell disease patients live in the NYC area.

  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
              

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.